Table 2. Univariate analysis of objective response rate of erlotinib treatment in lung adenocarcinoma patients without detectable EGFR mutations at initial molecular testing.

	Patient No.	ORR (%)	P value
Gender			0.209
Male	162	12.3
Female	99	18.2
Age (yrs)			0.478
≤ 65	158	13.3
> 65	103	16.5
ECOG PS			0.358
0–1	174	16.1
≧ 2	87	11.5
Smoking			0.113
NS	138	18.1
C/FS	123	10.6
EGFR methods			0.843
Direct sequencing	191	14.1
Sensitive methodsa	70	15.7

ORR, objective response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; NS, nonsmoker; C/FS, current or former smoker; EGFR, epidermal growth factor receptor.

^aInclude Scorpions ARMS, MALDI-TOF MS and PNA-LNA PCR clamp methods.